Share |

Content about Biology

August 9, 2011

Stella went into the hospital with a pain so great it cripples her entire being.  “It feels like a stabbing needle pain that shoots through my joints” she said.  No longer able to carry on her day to day routine she finally gives in after a few pills of over-the-counter pain medication did not work, and heads to the emergency room.  Her body is used to taking high doses of pain medication to alleviate the pain, so no regular pill will work.  The doctors and nurses in the hospital are too familiar with the patient; the only

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

July 29, 2015

Treatment for chronic hepatitis B (CHB) has improved significantly in the last 10 years but despite those improvements  360 million people or 5 percent of the world’s population remain chronically infected by the Hepatitis B virus (HBV). That's according to Gaithersburg, Md-based Vaxin Inc, the company recently announced that it has initiated Phase 1 clinical stage trial to test a vaccine treatment for HepTcell, its' immunotherapeutic compound to treat people who are chronically infected with HBV.

July 20, 2015

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

July 8, 2015

Washington, D.C.-based Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the European Union (EU) has approved its HETLIOZ (tasimelteon) drug to be used to treat non-24-hour sleep-wake disorder, also known as Non-24, in totally blind adults.

Non-24 is a chronic, circadian rhythm disorder. It disturbs the normal human sleep-wake cycle and mostly affects totally blind people. Disturbed sleep can lead to stress and also affects coordination. In the EU, around 130,000 people have been affected by this disorder.

March 23, 2012

Sodexo, with North American headquarters in Gaithersburg, will begin to service an estimated 2 million visitors under a food service contract from the Smithsonian National Zoological Park in Washington, D.C.

The 10-year contract makes Sodexo, the National Zoo's new partner for providing foodservice. The company will work with Friends of the National Zoo (FONZ), offering café, concessions, catering services and new dining options at 22 sites throughout the National Zoo.

December 19, 2011

Biodefense firm, PharmAthene, Inc. (NYSE Amex: PIP) announced that the Delaware Court of Chancery has denied competitor SIGA Technologies an appeal to the Court's decision on September 22, 2011.

With that ruling PharmAthene will receive 50 percent of net profits from the sale of ST-246, a smallpox antiviral drug being sold by SIGA. PharmAthene will receive the profits for 10 years after the first $40 million is accrued by SIGA. In addition, SIGA will pay one-third of attorney fees and witness costs.

October 25, 2011

The Maryland biotech said increased loss was due to higher selling, general and administrative expenses

Rockville-based Human Genome Sciences, Inc. (Nasdaq: HGSI) which launched Benlysta -- the first Lupus Drug in 56 years -- reported full quarter sales of it first consumer product.

The biotechnology company that partnered with GlaxoSmithKline PLC (NYSE: GSK) for Benlysta development said U.S. gross sales of the drug amounted to $21.3 million; net sales of the product were $18.8 million. That compares with $7.8 million of Benlysta sales in second quarter of 2011 although product delivery was not at full strength.

August 16, 2011

PharmAthene, Inc. (AMEX: PIP), an Annapolis based biodefense company, announced that they have been awarded $5.7 million by the Department of Defense (DoD) to continue research of its nerve agent medical countermeasure program.

The contract will allow PharmAthene to evaluate mammalian cell-based manufacturing system for rBChE for a period of 18 months. The company indicated that if the research is successful, it could increase production, flexibility, and be cost-effective.

August 4, 2011

Rockville-based Micromet, Inc reported financial results for the second quarter of 2011 ended June 30.

The biotechnology company developing new treatments for cancer said revenues totaled $7.062 Million in the quarter, a small increase from $6.5 Million in the second quarter ended the same time last year.

Net loss widened by a large margin falling over $13 Million to $17.3 Million ($-0.19 cents per basic and diluted share) in the quarter versus a net loss of $4.062 Million ($-0.05 cents per basic and diluted share) in 2010.

July 13, 2011

Annapolis based biotechnology company PharmAthene, Inc has reached a pivotal milestone in its development of an Anthrax prevention drug.

The biodefense biotech said that its SparVax™ rPA Anthrax Vaccineachieved a 36 month final product stability.

July 11, 2011

Press Release

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

- Collaboration on up to three targets and two programs
- Upfront payment of EUR 10 million upon deal execution
- Maximum deal value of EUR 695 million plus royalties and development cost reimbursement

ROCKVILLE, Md., Jul 11, 2011 (BUSINESS WIRE) --